Sentences with phrase «cell tumor at»

Treatment with a combination chemotherapy protocol was initiated and extremely effective at inducing remission of the mast cell tumor at the primary tumor site and lymph node.

Sometimes cats will develop other, unrelated basal cell tumors at other body sites.

Not exact matches

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

At the end of September, the European Commission approved a marketing application for Lutathera, a radioactive molecule that targets specific receptors found on the surface of neuroendocrine tumor cells.

Since PSMA's limited on normal cells, the therapy should hammer away at tumors while letting healthy tissues do their job.

However, the impact of the two methylation - regulating enzymes was still seen at 10 to 15 months, when scientists found decreased expression of hundreds of genes — many of which are key tumor suppressor genes such as BMP3, SFRP2 and GATA4 — in the smoke - exposed cells and a five - or - more-fold increase in the signaling of the KRAS oncogene that is known to be mutated in smoking - related lung cancers.

An immune response, triggered by foreign neural stem cells, could actually help attack tumors, says Evan Snyder, a stem cell biologist at Sanford Burnham Prebys Medical Discovery Institute in San Diego, California, and one of the early pioneers of the idea of using stem cells to attack tumors.

«Once this novel tumor - homing agent binds to the EphA2 receptor, the oncogene functions as a cancer - specific molecular Trojan horse for paclitaxel, carrying the drug inside the cancel cell, killing the cell, and thwarting metastasis,» said Maurizio Pellecchia, a professor of biomedical sciences at UCR's School of Medicine who led the research.

Images show tumor cells in a mouse brain at different days.

One of his professors, Dag Jenssen, persuaded Helleday to join his lab in the Department of Genetics, Microbiology, and Toxicology at Stockholm University to investigate the importance of recombination in somatic cells, tumor cells, and cancer initiation.

A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Understanding how margin length decreases from surgery to pathology — because of how the removed tissue shrinks and tumor cells invade surrounding tissues — can lead to better surgical margin planning and in turn a better prognosis, said corresponding author Milan Milovancev, a board - certified veterinary surgeon at OSU's College of Veterinary Medicine.

«There was this initial thought that [circulating tumor cells] are only present at late stage,» says Sollier - Christen, but she notes that in the past year, several studies using more sensitive techniques have found such cells much earlier in tumor development, even before the tumor becomes visible by conventional imaging techniques.

This pilot research builds on an earlier study by Milovancev and collaborators that examined the ability of MRIs and CT angiograms to detect cancerous lesions related to FISS, and another study that looked at three methods for assessing margins for canine mast cell tumors and soft tissue sarcomas.

A successful test would therefore require isolating enough of these scarce cells to make statistically valid inferences about the tumor, often at a stage when the tumor itself is growing and changing rapidly.

Studies suggest that stem cells sustain deadly tumors in the brain — and that aiming at these insidious culprits could lead to a cure

«We're interrogating the tumor microenvironment,» she says, «by looking at suppressive cues as well as cells and secreted proteins that protect tumors from the immune response.»

That type of fine - grained control is also revealing that at least some tumors may begin releasing cells sooner than scientists had realized.

In the upper panel, tumor cells formed colonization at day 14, while in the lower panel, when the mouse was treated with the compound edelfosine, most of the tumor cells disappeared at day 10 and failed to form colonization at day 14.

«Circulating tumor cells have the advantage that they are... intact living cells,» says Michael Kazinski, senior director and head of global product management for sample technologies at Qiagen in Hilden, Germany.

When the dendritic cells are activated, they train T cells — their allies in the adaptive arm of the immune system — to attack cancer cells anywhere in the body, whether at the site of the original tumor or distant metastases.

According to Srikumar P. Chellappan, Ph.D., chair of the Department of Tumor Biology at Moffitt, «these cells can also contribute to the metastasis of tumors as well as the reappearance of tumors after they have been eliminated from the body.»

Scientists at the Rosalind Franklin University of Medicine and Science in Chicago found a «remarkable similarity» between the cells that support the growth and development in placentas and in tumors.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Heacell research at Moores Cancer Center at UC San Diego Health.

«This combinational treatment also was well tolerated and enhanced the number of CD8 T cells at the tumor site.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

«Few drugs have the capacity to cross the tumor blood - brain barrier and specifically target tumor cells,» says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC — James.

Conventional, high - dose chemotherapy treatments can cause the fibroblast cells surrounding tumors to secrete proteins that promote the tumors» recurrence in more aggressive forms, researchers at Taipei Medical University and the National Institute of Cancer Research in Taiwan and University of California, San Francisco, have discovered.

The team led by Andreas Plückthun, Director of the Department of Biochemistry at the University of Zurich, involving postdoc Rastik Tamaskovic and PhD student Martin Schwill, has now found out why these antibodies merely slow tumor growth rather than killing off the cancer cells.

An experimental drug in early development for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)-- an indication of how aggressively the tumor cells may behave — and the prostate specific antigen (PSA) level in the patient's blood at the time of diagnosis.

Restoring normal function to a mutated protein is more difficult than simply blocking a protein, the strategy used by most medical therapies, says Klas Wiman, a tumor cell biologist at the Karolinska Institute in Stockholm.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

But following the removal of the primary tumor, micrometastatic cells learn to communicate with cells in their new microenvironment in the brain — cells which are, at first, hostile to them.

Published in Molecular Neurobiology, the study led by Dr Elodie Siney under the supervision of Dr Sandrine Willaime - Morawek, Lecturer in Stem Cells and Brain Repair at the University, analysed how enzymes called ADAMs affect the movement and function of the human tumor cCells and Brain Repair at the University, analysed how enzymes called ADAMs affect the movement and function of the human tumor cellscells.

Dr. Del Maestro adds, «Yong and colleagues at the University of Calgary have begun to unravel the complex interaction of the microglia with the brain tumor cells, resulting not only in furthering our understanding, but providing a new concept and drug which can now be immediately assessed in clinical trials.»

«Rac1 levels in invadopodia of invasive tumor cells appear to surge and ebb at precisely timed intervals in order to maximize the cells» invasive capabilities,» said Dr. Hodgson.

«What we may be looking at,» he adds, «is a future way to prevent metastasis to many organs simultaneously» using drugs that make tumor cells let go of the blood vessels they cling to.

Researchers at the University of Iowa did just that, documenting in real time and in 3 - D how melanoma cells form tumors.

In a series of experiments, the researchers first identified a set of 19 transcription factors that were expressed at significantly greater levels in cultured human glioblastoma stem cells capable of tumor propagation than in differentiated tumor cells.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Researchers led by Andreas Plueckthun, professor at the Department of Biochemistry at the University of Zurich, have now succeeded in rebuilding the viruses so that they effectively recognize and infect tumor cells.

Frequent, low - dose chemotherapy regimens avoid this effect and may therefore be more effective at treating certain types of breast and pancreatic cancer, according to the murine study «Metronomic chemotherapy prevents therapy - induced stromal activation and induction of tumor - initiating cells,» which will be published online November 23 in The Journal of Experimental Medicine.

«Different types of cancer cells with different strengths and weaknesses are both present in the tumor at the same time and can work together to spread faster and more efficiently.

When injected with cancer cells, animals housed there developed tumors 80 % smaller than those in control mice, or no tumors at all.

Today is the 70th birthday of Elizabeth Hay, an embryologist at Harvard Medical School who, through pioneering studies on regeneration of amphibian limbs, has shed light on the cellular mechanisms that transform normal cells into tumors.

The pathologist of the Department of Pathology at the University Hospital of Bellvitge August Vidal explained that «this tumorigenic transformation depends on Dicer protein that could serve as a marker for the presence of tumor cells, or as a therapeutic target.»

Chemotherapy aimed at killing single cells may not work as efficiently against bands of spreading tumor cells, she said.

Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth.

Oncologists William Hahn, Robert Weinberg, and colleagues at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, mutated the gene for one part of the enzyme and inserted it into cultured human cells from colon, ovary, and breast tumors.